Mesothelioma or Asbestos Question?

Patients Have Improved Survival Rate in Clinical Trial

Patients with inoperable malignant mesothelioma participated in a phase 3 clinical trial of combination drug therapy in Germany. The clinical trial studied the effects of taking Ranirnase along with Doxyrubicin instead of taking only the latter. The patients were given either the pair of drugs or Doxyrubicin and placebo.

The study showed that patients who took both drugs had a median survival rate of 11.1 months as opposed to the placebo group who had a survival rate of 10.7 months. In patients who had had other forms of chemotherapy previously, the combination group had a median survival rate of 10.5 months versus the 9 months of the placebo group.

If you would like to know more about mesothelioma treatment, contact us or go to

Leave a Reply





Home  |  Asbestos  |  Mesothelioma  |  Treatment  |  Exposure  |  Legal  |  News  |  Articles  |  Other Law Sites  |  Log in